Advertisement

Advertisement

Multiple Myeloma

Accelerated Approval Granted for Talquetamab-tgvs in Treatment of Relapsed or Refractory Multiple Myeloma

On August 9, 2023, the bispecific GPRC5D (G protein–coupled receptor, class C, group 5)-directed CD3 T-cell engager talquetamab-tgvs was granted accelerated approval by the U.S. Food and Drug Administration for treatment of adults with relapsed or refractory multiple myeloma who have received at...

Multiple Myeloma
Issues in Oncology

The Immune System May Play Vital Role in Remission Duration Among Patients With Multiple Myeloma

Researchers have uncovered the vital role that the immune system may play in determining the duration of remission and progression-free survival in patients with multiple myeloma, according to a recent study published by Coffey et al in Nature Communications. The new findings suggested that the...

Multiple Myeloma

Relapsed or Refractory Multiple Myeloma: Mezigdomide Plus Dexamethasone

In a phase I/II trial (CC-92480-MM-001) reported in The New England Journal of Medicine, Paul G. Richardson, MD, and colleagues found that the combination of the novel cereblon E3 ubiquitin ligase modulator mezigdomide and dexamethasone showed activity in heavily pretreated patients with relapsed...

Multiple Myeloma

FDA Approves New Multiple Myeloma Combination Therapy

On September 11, the U.S. Food and Drug Administration (FDA) approved motixafortide (Aphexda) in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. Motixafortide is...

Multiple Myeloma

More on Multiple Myeloma From ASCO 2023: Focus on Bispecific Antibodies

Two new bispecific antibodies—teclistamab and talquetamab—have been shown to be active in relapsed or refractory multiple myeloma when used in combination, including in patients with extramedullary disease, without compounding toxicity. Results of two clinical trials with these two agents were...

multiple myeloma

Nikhil Munshi, MD, on Multiple Myeloma: Data From the CARTITUDE-1 Study of Ciltacabtagene Autoleucel

Nikhil Munshi, MD, of Dana-Farber Cancer Institute, discusses the final safety and efficacy results from the phase Ib/II CARTITUDE-1 trial of ciltacabtagene autoleucel. This CAR T-cell therapy targets B-cell maturation antigen in patients with relapsed or refractory multiple myeloma. Longer median progression-free survival was observed after a single infusion of this agent than any previously reported therapy in heavily pretreated patients (Abstract S202).

Multiple Myeloma

Accelerated Approval for Elranatamab-bcmm in Patients With Relapsed or Refractory Multiple Myeloma

On August 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to elranatamab-bcmm (Elrexfio), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myeloma who have received at least four prior...

Multiple Myeloma

Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma

In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple myeloma.1 Of note, the safety profile confirmed results of the phase I portion of the study (recently published in TheNew England Journal...

Multiple Myeloma

Expert Point of View: Urvi A. Shah, MD

Urvi A. Shah, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor at Weill Cornell Medicine, New York, moderated the session where the MagnetisMM trial updates1,2 were reported and was interviewed by The ASCO Post. Elranatamab vs Teclistamab Dr. Shah noted...

Multiple Myeloma

Elranatamab Induces Responses in Many Patients With Resistant Multiple Myeloma in Phase II Trial

The promise of bispecific monoclonal antibodies in multiple myeloma continues to heighten as yet another one appears to be active. In a study reported at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition,1 almost two-thirds of patients with triple-refractory disease who...

Multiple Myeloma

FDA Grants Accelerated Approval to Talquetamab-tgvs for Treatment of Relapsed or Refractory Multiple Myeloma

On August 9, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the bispecific antibody talquetamab-tgvs (Talvey) for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (including a proteasome inhibitor, an...

Multiple Myeloma
Immunotherapy

Ciltacabtagene Autoleucel vs Standard Care in Lenalidomide-Refractory Patients With Multiple Myeloma

In the phase III CARTITUDE-4 trial reported in The New England Journal of Medicine, San-Miguel et al found that receipt of ciltacabtagene autoleucel following bridging therapy significantly improved progression-free survival vs standard care in lenalidomide-refractory patients with multiple...

Multiple Myeloma
Supportive Care

Acupuncture May Improve Sleep Among Patients With Multiple Myeloma Undergoing HSCT

An ancient practice may offer modern relief for sleep disturbances experienced by patients with multiple myeloma undergoing hematopoietic stem cell transplant (HSCT), according to research published by El Iskandarani et al in Acupuncture in Medicine. Based on a randomized, prospective study of 63...

Multiple Myeloma
Immunotherapy

Crenigacestat Plus BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

In a single-institution, phase I, first-in-human trial reported in The Lancet Oncology, Cowan et al found that the combination of the γ-secretase inhibitor (GSI) crenigacestat and B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy was tolerable and produced a high...

Multiple Myeloma

Academically Developed BCMA-Directed CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

In an interim analysis of a Spanish pilot trial (CARTBCMA-HCB-01) reported in The Lancet Oncology, Oliver-Caldés et al found that an academically developed B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, ARI0002h, showed activity in patients with relapsed...

Multiple Myeloma

Daratumumab Plus Chemotherapy as Induction and Extended Consolidation Therapy for Ultra–High-Risk Multiple Myeloma

In an analysis reported in the Journal of Clinical Oncology, Martin F. Kaiser, MD, and colleagues found that daratumumab plus low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd) used as induction and extended consolidation therapy in newly diagnosed patients with...

Multiple Myeloma
Genomics/Genetics

Research Sheds Light on the Evolution of Precursor Conditions to Multiple Myeloma

Researchers have shared novel insights into the evolution of multiple myeloma from precursor disease, which may help physicians better identify patients whose disease is likely to progress as well as develop new interventions, according to a recent study published by Dang et al in Cancer Cell. How...

Multiple Myeloma
Supportive Care

Exercise May Strengthen Immune System in Patients With Multiple Myeloma

Researchers have found that exercise may be effective at strengthening the immune system in patients with multiple myeloma, providing them with a nonpharmaceutical method of managing the disease, according to new findings presented by Joseph et al at the 2023 ASCO Annual Meeting (Abstract 8060)....

Multiple Myeloma
Immunotherapy

Ciltacabtagene Autoleucel Reduces Risk of Disease Progression in Patients With Lenalidomide-Refractory Multiple Myeloma

Ciltacabtagene autoleucel, a B-cell maturation antigen–targeting chimeric antigen receptor (CAR) T-cell therapy, significantly slows or stops progression of multiple myeloma when compared with standard-of-care treatments among patients with lenalidomide-refractory disease. Results from the...

Multiple Myeloma
Genomics/Genetics

CRISPR Approach May Help Identify Therapeutic Targets in Patients With Multiple Myeloma

Researchers have identified 116 genes as key molecular vulnerabilities for multiple myeloma, according to a novel study published by de Matos Simoes et al in Nature Cancer. The findings demonstrated the potential for these genes to act as leads and help researchers discover new therapeutic options...

Multiple Myeloma
Immunotherapy

Highlighting Progress in Myeloma Treatment: POLLUX Trial Final Overall Survival Results With Daratumumab-Based Therapy

The updated results of the POLLUX trial, reported in the Journal of Clinical Oncology by Dimopoulos and colleagues and in this issue of The ASCO Post, showed significantly improved overall survival with daratumumab plus lenalidomide/dexamethasone (DRd) vs Rd in patients with previously treated...

Multiple Myeloma

Novel Bispecific Antibody for Multiple Myeloma Shows High Response Rates in Early Trial

The bispecific antibody REGN5459 achieved a 90.5% overall response rate when given at the two highest doses in patients with relapsed or refractory multiple myeloma, according to the results of a phase I/II clinical trial.1 Although preliminary, the results of this first-in-human trial for the...

Multiple Myeloma
Hematologic Malignancies

Novel Calculator May Identify Patients With Favorable-Prognosis Hematologic Cancers

Researchers have developed a calculator that may be capable of identifying patients who have multiple myeloma and light-chain amyloidosis with more benign profiles and, consequently, better prognoses, according to a novel study published by Burgos et al in the Journal of Clinical Oncology. The...

Multiple Myeloma
Issues in Oncology

Enrollment Criteria for Multiple Myeloma Clinical Trials May Exclude Patients From Racial and Ethnic Minorities

The parameters set to determine which patients can enroll in clinical trials testing new multiple myeloma treatments may disproportionately exclude patients from racial and ethnic minority groups, according to a new study published by Kanapuru et al in the journal Blood. Background Multiple myeloma ...

Multiple Myeloma
Immunotherapy

Bispecific Antibody REGN5459 Shows Activity in Patients With Relapsed or Refractory Multiple Myeloma

Although the 5-year relative survival rate for multiple myeloma is improving—up from 34.6% in 1998 to 53.9% in 2016—due to the approval of more effective therapies, multiple myeloma remains incurable, and new treatment options are needed, especially in the relapsed/refractory setting. A small phase ...

Multiple Myeloma

Significance of the MGUS-Like Phenotype in Patients With Multiple Myeloma and Light Chain Amyloidosis

In a study reported in the Journal of Clinical Oncology, Burgos et al developed an algorithm to identify patients with multiple myeloma and light-chain amyloidosis who have the monoclonal gammopathy of undetermined significance (MGUS)-like phenotype, as well as identified the association of the...

Multiple Myeloma
Immunotherapy

Idecabtagene Vicleucel vs Standard Regimens in Patients With Relapsed or Refractory Multiple Myeloma

As reported in The New England Journal of Medicine by Paula Rodriguez-Otero, MD, PhD, of Clínica Universidad de Navarra, Pamplona, Spain, and colleagues, an interim analysis of the phase III KarMMa-3 trial has shown superior progression-free survival with the B-cell maturation antigen–directed...

Multiple Myeloma

Activity of Novel CAR T Cells in Relapsed or Refractory Multiple Myeloma

In a Chinese single-center phase II trial reported in the Journal of Clinical Oncology, Xia et al found that anti–G protein–coupled receptor, class C group 5 member D (GPRC5D) chimeric antigen receptor (CAR) T cells showed activity in patients with relapsed or refractory multiple myeloma. Study...

Multiple Myeloma

Dan T. Vogl, MD, Comments on Follow-up of the UK NCRI Myeloma XI Trial

Dan T. Vogl, MD, Associate Professor of Medicine at the Hospital of the University of Pennsylvania and Director of the Abramson Cancer Center at the Perelman School of Medicine, Philadelphia, told The ASCO Post that the follow-up of the UK NCRI Myeloma XI trial confirms the importance of...

Multiple Myeloma

When Can You Stop Lenalidomide Maintenance in Myeloma?

A study aimed at determining the optimal duration of lenalidomide maintenance after autologous stem cell transplantation for multiple myeloma has not answered that question, per se, but has yielded some hints that may inform future clinical trials. The follow-up analysis of the UK NCRI Myeloma XI...

Hematologic Malignancies
Multiple Myeloma

Studies Focusing on Age- and Race-Related Disparities in Multiple Myeloma and Sickle Cell Disease

Research that addresses the compounding effects of age and race/ethnicity on access to quality health care and patient-centered outcomes such as physical function, frailty, and survival continues to be an emerging area of inquiry in hematology. Accordingly, novel research employing qualitative and...

Multiple Myeloma
Immunotherapy

KarMMa-3: Idecabtagene Vicleucel vs Standard Regimens in Patients With Relapsed or Refractory Multiple Myeloma

As reported in The New England Journal of Medicine by Rodriguez‑Otero et al, an interim analysis of the phase III KarMMa-3 trial showed superior progression-free survival with the B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel (ide-cel) vs...

Multiple Myeloma

Neighborhood Social Vulnerability and Its Influence on the Availability of Clinical Trials in Multiple Myeloma

Clinical trials set the treatment standards for cancer care. However, for select populations, such as those who are older, Black, or facing socioeconomic challenges, access to clinical trials and health care generally remains limited. Barriers to clinical trial participation are numerous and...

Multiple Myeloma

Expert Point of View: Robert Rifkin, MD

Smoldering myeloma is an asymptomatic plasma cell disorder with a heterogeneous clinical behavior. Two trials presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition investigated early intervention for smoldering multiple myeloma, aiming for a “curative strategy”...

Multiple Myeloma

Triplet and Quadruplet Regimens in Smoldering Multiple Myeloma

Combination regimens beyond lenalidomide/dexamethasone were shown to significantly delay—and potentially prevent altogether—progression from smoldering disease to active multiple myeloma, according to researchers who reported findings from two studies at the 2022 American Society of Hematology...

Multiple Myeloma

Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma

In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple myeloma.1 Of note, the safety profile confirmed results of the phase I portion of the study (recently published in TheNew England Journal...

Multiple Myeloma

Expert Point of View: Urvi A. Shah, MD

Urvi A. Shah, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor at Weill Cornell Medicine, New York, moderated the session where the MagnetisMM trial updates1,2 were reported and was interviewed by The ASCO Post. Elranatamab vs Teclistamab Dr. Shah noted...

Multiple Myeloma

Expert Point of View: Urvi A. Shah, MD

Urvi A. Shah, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor at Weill Cornell Medicine, New York, moderated the session where the MagnetisMM trial updates1,2 were reported and was interviewed by The ASCO Post. Elranatamab vs Teclistamab Dr. Shah noted...

Multiple Myeloma

Elranatamab Induces Responses in Many Patients With Resistant Multiple Myeloma in Phase II Trial

The promise of bispecific monoclonal antibodies in multiple myeloma continues to heighten as yet another one appears to be active. In a study reported at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition,1 almost two-thirds of patients with triple-refractory disease who...

Multiple Myeloma

Significant Benefit With Addition of Daratumumab to Bortezomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma

As reported in the Journal of Clinical Oncology by Pieter Sonneveld, MD, PhD, of Erasmus MC Cancer Institute, Rotterdam, the Netherlands, and colleagues, the final overall survival analysis of the phase III CASTOR trial has shown a significant benefit of the addition of daratumumab to...

Multiple Myeloma
Immunotherapy

Real-World Use of Idecabtagene Vicleucel for Patients With Relapsed or Refractory Multiple Myeloma

In a retrospective study of the real-world use of idecabtagene vicleucel reported in the Journal of Clinical Oncology, Hansen et al found that response rates and toxicity in patients with relapsed or refractory multiple myeloma were comparable to those in the pivotal phase II KarMMa trial; the...

Multiple Myeloma

ASH 2022: Multiple Myeloma Highlights

The 2022 American Society of Hematology (ASH) Annual Meeting and Exposition was full of interesting abstracts in multiple myeloma. In addition to full coverage of several important presentations, The ASCO Post offers readers quick takes on some studies that could be practice-changing and others...

Multiple Myeloma

Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma

In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple myeloma.1 Of note, the safety profile confirmed results of the phase I portion of the study (recently published in TheNew England Journal...

Multiple Myeloma

Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide in Maintenance Therapy After ASCT in Newly Diagnosed Multiple Myeloma

As reported in The Lancet Oncology by Dominik Dytfeld, MD, PhD, and colleagues, an unplanned interim analysis of the phase III ATLAS trial has shown improved progression-free survival with carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide alone as maintenance after autologous stem...

Multiple Myeloma

POLLUX Trial Final Overall Survival Analysis: Addition of Daratumumab to Lenalidomide/Dexamethasone in Previously Treated Patients With Multiple Myeloma

As reported in the Journal of Clinical Oncology by Meletios A. Dimopoulos, MD, and colleagues, the final overall survival analysis of the pivotal phase III POLLUX trial has shown a significant benefit with the addition of daratumumab to lenalidomide and dexamethasone after a median follow-up of...

Multiple Myeloma

FORTE Trial of Carfilzomib-Containing Induction, Consolidation, and Maintenance in Newly Diagnosed Multiple Myeloma: Subgroup Analysis by Cytogenetic Risk

In a prespecified analysis of the Italian phase II FORTE trial reported in The Lancet Oncology, Mina et al identified outcomes associated with the number of high-risk cytogenetic abnormalities (HRCAs) across treatment groups receiving carfilzomib-containing induction, consolidation, and maintenance ...

multiple myeloma

Paul G. Richardson, MD, on Multiple Myeloma: Mezigdomide Plus Dexamethasone in Relapsed and Refractory Disease

Paul G. Richardson, MD, of the Dana-Farber Cancer Institute, discusses preliminary results from the dose-expansion phase of the CC-92480-MM-001 Trial, which showed promising efficacy in patients with relapsed and refractory multiple myeloma, including those with prior BCMA-targeted therapies. Patients in these two groups had an overall response rate of 40% and 50%, respectively. The results support the development of mezigdomide, currently being evaluated in combination with standard therapies in multiple myeloma as part of a large, ongoing phase I/II trial (NCT03989414) and planned phase III studies (Abstract 568).

Multiple Myeloma

Modakafusp Alfa May Be Effective at Treating Patients With Multiple Myeloma

The novel drug modakafusp alfa has shown early promise in combating relapsed/refractory multiple myeloma, according to new findings presented by Vogl et al at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 565). Background Modakafusp alfa is a fusion protein...

Multiple Myeloma

Genome Sequencing of Circulating Tumor Cells in Detection of Myeloma and Precursor Conditions

The novel MinimuMM-seq technique may make it possible to detect tumor cells in individuals at higher risk for multiple myeloma, assess the risk of disease progression in patients with myeloma, and track genetic changes in tumor cells over time from a single blood sample, according to a new study...

multiple myeloma
genomics/genetics
immunotherapy

Jiye Liu, PhD, on Multiple Myeloma: Genome-Wide CRISPR-Cas9 Screening Identifies KDM6A as a Modulator of Daratumumab Sensitivity

Jiye Liu, PhD, of Dana-Farber Cancer Institute, discusses study findings that demonstrate KDM6A regulates CD38 and CD48 expression in multiple myeloma. Dr. Liu’s team validated combination treatment with an FDA-approved EZH2 inhibitor plus daratumumab, which can overcome daratumumab resistance in preclinical multiple myeloma models, providing the rationale for combination clinical trials to improve patient outcome (Abstract 148).

Advertisement

Advertisement

Advertisement